MétaCan
Menu
Back to cohort
Record W2998046891 · doi:10.1002/ejhf.1276

December 2019 at a Glance: Economic Burden, Co-Morbidities, and Prognosis

2019· article· en· W2998046891 on OpenAlexaff
Marianna Adamo, Carlo Lombardi, Marco Metra

Bibliographic record

VenueEuropean Journal of Heart Failure · 2019
Typearticle
Languageen
FieldMedicine
TopicCardiovascular Issues in Pregnancy
Canadian institutionsSurgical Specialties (Canada)
Fundersnot available
KeywordsMedicineHeart failureEjection fractionNatriuretic peptideInternal medicineCardiologyIntensive care medicine

Abstract

fetched live from OpenAlex

Heart failure (HF) is associated with high healthcare costs, and trials to reduce them may be disappointing.1 Bundgaard et al.2 investigated direct and indirect costs of HF performing a 1:1 matched comparison between diseased and healthy subjects from the Danish nationwide registry. Patients with HF incurred an average of €17 039 in total annual direct (€11 926) and indirect (€5113) costs compared to €5936 in the control group, with most of the costs caused by hospitalizations. The cost related with HF peaked at the year of first diagnosis but started to increase as early as 2 years before diagnosis. Peripartum cardiomyopathy is a major complication of pregnancy.3 Moulig et al.4 reported 5-year results of their German registry. Most of the patients (95%) had an improvement in left ventricular function with 72% who achieved full recovery. Mortality was low (2%). Long-term use of HF drugs was observed in 70% of cases. We have no therapy for HF with preserved ejection fraction (HFpEF) and experimental models are difficult.5 Primessnig et al.6 tested a specific Na+/Ca2+ exchanger inhibitor in a rat model of HFpEF. Chronic treatment attenuated cardiac remodelling and diastolic dysfunction without no effect on blood pressure. Biomarkers predict prognosis in patients with acute HF.7 Wettersten et al.8 investigated the relationship between B-type natriuretic peptide (BNP) and worsening renal function (WRF) and its prognostic implications in a multicentre registry of patients with acute HF. Decreased BNP was associated with better early and mid-term outcomes regardless of WRF, while WRF was associated with poorer outcomes only in patients with no BNP reduction. Different from a previous analysis based on pre-discharge values,9 plasma renin activity measured on admission had a modest, but significant, association with outcomes in patients with acute HF.10 Abnormal breathing control is associated with poor prognosis in chronic HF.11 The detection of oscillatory ventilation during exercise predicted cardiovascular death, urgent heart transplant, and ventricular assist device implantation in patients with HF and mid-range or reduced ejection fraction.12 Atrial fibrillation (AF) is associated with poorer outcomes and worse symptoms in HF patients.13 The role of the left atrium in this relationship is poorly known. Inciardi et al.14 investigated the association between left atrial (LA) structure/function and risk of cardiovascular death or HF hospitalization in patients with AF enrolled in the Effective Anticoagulation with Factor Xa Next Generation in AF-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. The composite endpoint occurred in 15% of patients at a median follow-up of 2.5 years. Measures of impaired LA function, LA emptying fraction and LA expansion index, were the only independent predictors of clinical events. Cancer is a common co-morbidity in HF patients.15 De Boer et al.16 reviewed the most recent data regarding the relationship between HF and cancer. This review analyses the epidemiology, risk factors and pathophysiological mechanisms shared by these two conditions. Vericiguat may improve symptoms and quality of life in patients with chronic HF.17 The Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial will establish the impact of vericiguat on outcomes. Baseline characteristics of the patients enrolled in this trial are reported showing a high-risk population despite optimal medical treatment.18 Lung ultrasound (LUS) is a useful tool to evaluate clinical congestion in HF patients.19 In the LUS-HF trial patients admitted for HF were randomized to either standard therapy or LUS-guided therapy up to 6 months. Tailored LUS-guided therapy reduced the risk of the primary endpoint (urgent visit or hospitalization for HF or death) and improved functional capacity.20 Iung et al.21 reported the 2-year results of the Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation (MITRA-FR) trial, confirming the lack of benefit of percutaneous edge-to-edge mitral valve repair over medical therapy in reducing death or unplanned HF hospitalization in this trial.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesInsufficient payload (model declined to judge)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.097
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.247
Teacher spread0.238 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Journal of Heart FailureSame topicCardiovascular Issues in PregnancyFrench-language works237,207